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depression. Our objective was to see if depression was present
in patients undergoing treatment for chronic pain with opioids
and if improving pain, improves depression. METHODS: A
standardized depression scale was administered to chronic stable
pain patients on opioids for chronic non-malignant pain. They
were scored and ranked. RESULTS: Out of 98 patients, only
15% had minimal to no depression by standardized testing.
There was good correlation with subsequent clinical evaluation.
Eighty-ﬁve percent (85%) had mild to severe depression. Those
with moderate to severe depression were referred for specialty
consultation. CONCLUSIONS: Depression is common in
chronic pain and the level of depression may not be predicted by
level of pain, analgesic, anti-depressant useage, or mental health
follow-up. Depression is easily missed and under-treated.
Depression does not always respond to the concomitant treat-
ment of pain. Patients with chronic pain should be regularly
screened for depression and appropriately referred for care.
PPN1
ESTIMATING THE INCIDENCE AND COSTS OF TREATING
ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG
OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN
Morris J, Berry P
Napp Pharmaceuticals, Cambridge, UK
OBJECTIVE: Patients receiving strong opioids for chronic non-
malignant pain frequently experience adverse events, placing a
considerable burden on the patient and health care system. Evi-
dence suggests adverse event rates may vary between treatments.
METHODS: Patients treated with strong opioids for non-
malignant pain were identiﬁed using the General Practice
Research Database (GPRD). Three cohorts were identiﬁed: oral
oxycodone, oral modiﬁed release morphine, transdermal fen-
tanyl. Patients were matched for age, gender, morphine equiva-
lent dose and prior exposure to strong opioids. Adverse events
of interest were constipation and nausea and vomiting. Six
months of data were collected for each patient either side of their
ﬁrst prescription date (index date) for a strong opioid. Incidence
of treated adverse events was identiﬁed by prescription of laxa-
tives and anti-emetics during the 6-month post index, where no
prescription was present during the 6-month pre-index. Treat-
ment costs were estimated using the BNF. The chi square test
was used to test for differences in adverse event rates. RESULTS:
Incidence of constipation requiring treatment was estimated at
15% in the oxycodone cohort, 15% in the fentanyl cohort and
22% in the morphine cohort. Rates for oxycodone and fentanyl
were signiﬁcantly lower than morphine (p < 0.05). For nausea
and vomiting rates were 11%, 14%, and 14% respectively with
no signiﬁcant differences between cohorts. Mean treatment cost,
per case of constipation, was £19.34 for oxycodone, £41.71 for
fentanyl and £31.79 for morphine. For nausea and vomiting
costs were £13.10, £22.06 and £11.09. CONCLUSION: Patients
treated with morphine for non-malignant pain in this study were
more likely to be treated for constipation compared to oxy-
codone or fentanyl. Treatment for nausea and vomiting was
equally likely across treatment cohorts. Differences were
observed in the mean cost associated with adverse event treat-
ment. Further research would be valuable to conﬁrm the ﬁnd-
ings of this study.
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RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN
CONDITIONS BEFORE AND DURING TREATMENT WITH
LONG-ACTING OPIOIDS IN GERMANY
Burkowitz J, Brüggenjürgen B
Alpha Care GmbH, Celle, Germany
OBJECTIVES: Although use of long-acting opiod analgesics has
increased for chronic pain, little is known about treatment 
patterns. Purpose of this study was to compare ofﬁce-based 
utilisation data before and after initiating treatment with 
different long-acting opioids. METHODS: Retrospective analy-
sis of Disease Analyzer (MediPlus) data over 5 years for patients
with malignant diseases and orthopaedic diseases/chronic pain.
Patients have not been treated with opioids in the 18 months
before prescription. Observation period for resource utilisation
(outpatient consultations, referrals, dug costs) started 6 months
before and ended 6 months after ﬁrst index prescription for the
long-acting opioid of interest. RESULTS: Corresponding to the
course of the disease number of referrals, consultations, costs of
other drugs except of analgesics increased after initial prescrip-
tion of opioids. When opioids were administered, costs for other
analgesics decreased slightly compared to the pre-opioid period.
Drug costs differed signiﬁcantly. Highest opioid costs were deter-
mined for patients with malignant diseases which were treated
with fentanyl (mean 681€ in ﬁrst six months), followed by oxy-
codone (412€) and morphine (321€). Costs for opiod treatment
for patients with non-malignant chronic pain and orthopedic
conditions were 589€ (fentanyl), 370€ (oxycodone) and mor-
phine (243€) respectively. No signiﬁcant differences for costs for
other medication were found. Patients treated with oxycodone
showed signiﬁcant less consultations compared to fentanyl or
morphine. CONCLUSION: Type of opioid is an important
factor for costs of treatment of chronic pain in the ofﬁce-based
setting in Germany. The analysis indicates that other resource
utilization like consultation of physician could also be inﬂu-
enced. Due to the observational and retrospective nature of the
database study patient reported outcomes were not included.
Thus these outcomes and direct costs from hospitals associated
with long-acting opioids treatment would merit further analysis
in Germany.
PPN3
AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENT-
CONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN
ACADEMIC MEDICAL CENTER
Zhang M1,Viscusi E2, Costello A2,Vallow S3, Johnson N4
1Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; 2Thomas Jefferson
University, Philadelphia, PA, USA; 3Janssen Medical Affairs, LLC,
Titusville, NJ, USA; 4Outcomes Research and Design, Inc, Houston,
TX, USA
OBJECTIVES: Intravenous patient-controlled analgesia (IV
PCA) is widely used for postoperative pain management. The
objectives of this pilot observational study were to deﬁne the
tasks and personnel required for IV PCA administration and to
identify problems arising with use of this modality. METHODS:
This study was conducted at a single site academic medical center
in Philadelphia, PA, USA. Process ﬂow diagrams were developed
based on interviews and observations conducted in the central
supply, biomedical engineering, pharmacy, and nursing depart-
ments. The diagrams mapped all steps in the process of IV PCA
administration within each department. Problems related to IV
PCA administration were also recorded. RESULTS: Forty-two
patients who underwent hip replacement surgery were selected
for observation. Central supply collected, cleaned, and delivered
IV PCA pumps to appropriate locations, and delivered malfunc-
tioning pumps to biomedical engineering. Biomedical engineer-
ing evaluated malfunctioning pumps and performed routine
maintenance on all pumps. Pharmacy prepared IV PCA syringes
and delivered them to the nursing units. Nursing staff processed
IV PCA orders, obtained pumps and set them up, redressed or
restarted IV lines, educated patients, discontinued PCA, and
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completed the necessary documentation. Thirty-seven of 42
(88%) patients experienced at least one IV PCA-related problem,
with an average of 3.3 problems per patient. The most common
problems were drug-related (79%), including dose adjustments,
syringe replacement, and medication changes. Patient-related
problems were also common (45%), and included the need for
patient re-education regarding IV PCA use, assisting patients in
using the on-demand button, and addressing side effects related
to opioid use. IV PCA line problems and pump-related problems
were observed in 14% and 12% of patients, respectively. CON-
CLUSIONS: IV PCA administration requires a complex series of
processes and coordination among several hospital departments.
Problems with IV PCA are common and require staff time and
effort to resolve.
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COST-EFFECTIVENESS OF THE COMBINATION TRAMADOL
PLUS PARACETAMOL IN TREATMENT OF SUBACUTE LOW
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OBJECTIVES: To determine the cost-effectiveness of a combi-
nation tablet of tramadol/paracetamol (Zaldiar) versus tramadol
in the treatment of subacute low back pain in a Dutch Health
Care setting. The hypothesis was that higher drug costs for the
combination therapy are offset by a reduction of costs associated
with the treatment of side-effects. METHODS: Decision analy-
sis was used to model the health economic outcomes. A cost-
minimisation approach was appropriate since the efﬁcacy of the
two treatments proved to be the same in the dosages used. Prob-
abilities (side-effects), resource utilisation data (pain treatment
and treatment of side-effects), productivity losses and unit costs
were obtained from published literature, clinical trial reports,
Delphi panel and ofﬁcial price and tariff lists (Dutch costing
manual). The perspective taken was that of society and health
insurance. RESULTS: Compared with tramadol IR, savings with
combination therapy from a society perspective were 34.78€ per
patient for ten days’ treatment of subacute low back pain (costs
of combination therapy: 62.58€; with tramadol IR: 97.36€).
Savings with combination therapy from a health insurance per-
spective were 25.30€ (costs of combination therapy: 54.64€;
with tramadol IR: 79.94€). Sensitivity analyses conﬁrmed the
robustness of the model. CONCLUSIONS: The results show that
treatment with the combination tablet of tramadol/paracetamol
compared with tramadol IR is cost-saving and has fewer side-
effects. This is true despite the fact that with the dosages used
the daily drug costs of combination therapy are higher than those
of tramadol IR. The reason for the lower total therapy costs is
the lower incidence of side-effects with the combination tablet
of tramadol/paracetamol, resulting in favourable clinical and
economic beneﬁts.
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OBJECTIVES: The current treatment of neuropathic pain (NeP)
includes a wide range of drug and non-drug therapies, and
patient outcomes are not very satisfactorily. The aim of this study
was to assess the magnitude of, and to explore the relationship
between the health and economic burden of the condition in
patients treated at the specialist level. METHODS: Ninety-eigth
patients with NeP were included at random cross-sectionally in
4 pain centres, and were followed up prospectively during one
month. All medical resource use related to NeP as well as pain
scores (daily Visual Analogue Scale), were collected via patient
diaries. Quality of Life (MPI, MPQ and SF-36) was assessed at
start and at the end of the one month observation period. Costs
from the public insurance perspective were calculated by multi-
plying the medical resource use with charges. SF-36 scores were
transformed into utility values, using the SF-6D algorithm.
RESULTS: Patients had an average history of 4.5 years of NeP;
84% had peripheral NeP; 20% had mild pain, 80% moderate
or severe. The total monthly cost was 438.4€ (+/ 105.8). Hospi-
tal stays represented 57% of total costs. The utility at start was
0.550 (+/- 0.012) and at the end date 0.578 (+/- 0.012) (p =
0.005). A multivariate regression analysis showed an indepen-
dent and signiﬁcant inverse relationship between utility at start
and total cost (p = 0.011). In peripheral NeP, patients with mod-
erate to severe pain had a more than doubled cost compared to
patients with mild pain: 517€ (+/- 148) vs. 201€ (+/- 45) (p =
0.045). CONCLUSIONS: NeP is associated with rather utility
values in the order of magnitude of some cancer types. Higher
pain scores and lower utilities lead to higher cost of treatment.
A possible explanation for the slight but signiﬁcant increase in
utility is the increased attention within the study environment.
PAIN
PAIN—Quality of Life/Utility/Preference Studies
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OBJECTIVES: Aim of the survey was: 1) to identify character-
istics of patients with PND’s; 2) to quantify burden of health
resource utilisation among this patients; and 3) to investigate the
impact of PND’s and its treatment on productivity and daily
functioning. METHODS: In this cross-sectional, one-time survey
we focused on the documentation of self-reported functioning
and well-being, pain exerience, MD’s reported medication use,
productivity and employment status. Well established question-
aires / scals were used for data collection. RESULTS: A total of
202 patient questionnaires were eligible for data-analysis. Dia-
betic (n = 62) and Postherpetic (n = 33) neuropatic pain were
most prominent where 86% of the patients reported their worst
pain within the last 24 hours as moderate 33% or severe 53%
(all indications). The pain severity index results where nearly
similar but moderate was reported mostly (57%). EQ-5D-scores
was comparable for worst pain within the last 24 hours and pain
severity index and was low in patients reporting “severe pain
experience” (0.3/0.13). Ten percent (10%) of patients were early
retired, 12% were disabled due to neuropatic pain, 17% had to
reduce scheduled work and 27% of the patients reported a sus-
tantial reduction in work productivity because of their NeP.
Analgesics (77%) were prescribed most commonly followed by
antiepileptics (53%), antidepressants (37%) and Hypnotics
(30%). Combination is common. Patient satisfaction by using
the prescribed medication was high. In total, 21% were
“extremely satisﬁed” and 55% were “somewhat satisﬁed”.
CONCLUSIONS: Treatment of NeP should be optimized since
a high percentage of patients reported a considerable pain within
24h. However, it is astonishing that in general patients satisfac-
tion with their current treatment was high. The mismatch
